KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Resmed (RMD) Restructuring Costs (2016 - 2025)

Resmed (RMD) has disclosed Restructuring Costs for 8 consecutive years, with $5.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Restructuring Costs changed N/A year-over-year to $5.9 million, compared with a TTM value of $23.8 million through Dec 2025, up 137.02%, and an annual FY2025 reading of $2.0 million, changed N/A over the prior year.
  • Restructuring Costs was $5.9 million for Q4 2025 at Resmed, down from $15.8 million in the prior quarter.
  • Across five years, Restructuring Costs topped out at $64.2 million in Q4 2023 and bottomed at -$64.2 million in Q2 2024.
  • Average Restructuring Costs over 4 years is $4.8 million, with a median of $5.9 million recorded in 2025.
  • The sharpest move saw Restructuring Costs surged 664.62% in 2023, then plummeted 797.83% in 2024.
  • Year by year, Restructuring Costs stood at $8.4 million in 2022, then soared by 664.62% to $64.2 million in 2023, then tumbled by 199.96% to -$64.2 million in 2024, then surged by 109.24% to $5.9 million in 2025.
  • Business Quant data shows Restructuring Costs for RMD at $5.9 million in Q4 2025, $15.8 million in Q3 2025, and $2.0 million in Q2 2025.